AGTR1 and type 2 diabetes mellitus: Considering the significant impact of β-blockers on DPN development in the clinical study (see Table 2), the peripheral β-adrenoceptor/renin/Ang/AT1 receptor system appears to participate in DPN development accompanying T2DM, and may serve as therapeutic targets for DPN.